Want to see SCNX full AI Analyst Report?
Top Page
Scienture Holdings
(NASDAQ:SCNX)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.36
▼(-34.73% Downside)
Action:Reiterated
Date:07/11/26
The score is held down primarily by very poor profitability and significant cash burn (weak income statement and cash flow), with only partial offset from low recent leverage on the balance sheet. Technicals are neutral-to-weak with a negative MACD and price below longer-term averages, while valuation remains unattractive/unclear due to losses (negative P/E) and no indicated dividend support. The recent structured financing improves liquidity but introduces meaningful covenant and repayment-risk constraints.
Positive Factors
Low leverage on balance sheet
Very low recent leverage meaningfully reduces near-term solvency risk and preserves the company’s ability to access additional financing or support commercialization spending. This structural balance-sheet strength lengthens runway versus highly levered peers despite operating losses.
Negative Factors
Material cash burn
Consistently negative operating and free cash flow indicate the business consumes cash to operate and commercialize products. This structural cash burn forces repeated external financing, constrains discretionary R&D/commercial spending, and increases dilution or creditor dependence over months.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage on balance sheet
Very low recent leverage meaningfully reduces near-term solvency risk and preserves the company’s ability to access additional financing or support commercialization spending. This structural balance-sheet strength lengthens runway versus highly levered peers despite operating losses.
Read all positive factors
Scienture Holdings (SCNX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$15.04M
Dividend YieldN/A
Average Volume (3M)4.08M
Price to Earnings (P/E)―
Beta (1Y)3.25
Revenue Growth-73.18%
EPS Growth92.38%
CountryUS
Employees9
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)N/A
Shares Outstanding40,630,814
10 Day Avg. Volume11,411,402
30 Day Avg. Volume4,082,790
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.12
Price to Sales (P/S)181.35
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-234.53
Enterprise Value/Revenue-7.38K
Enterprise Value/Gross Profit35.69K
Enterprise Value/Ebitda89.40
Forecast
1Y Price Target
$1.50Price Target Upside172.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Scienture Holdings Business Overview & Revenue Model
Company Description
As a health services IT enterprise, TRxADE HEALTH, Inc. manages an online platform designed to facilitate transactions between licensed pharmaceutical wholesalers and healthcare providers. This digital marketplace enables wholesalers to distribute...
How the Company Makes Money
null...
Scienture Holdings Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
72
Positive
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 477.68K | 431.61K | 136.64K | 1.36M | 10.25M | 9.89M |
| Gross Profit | -98.81K | 331.48K | 6.00K | 49.03K | 5.52M | 4.75M |
| EBITDA | -39.45M | -38.93M | -17.39M | -6.29M | -1.87M | -5.15M |
| Net Income | -41.85M | -41.51M | 9.07M | -17.84M | -3.47M | -5.32M |
Balance Sheet | ||||||
| Total Assets | 80.66B | 84.18M | 104.85M | 12.53M | 3.71M | 5.77M |
| Cash, Cash Equivalents and Short-Term Investments | 3.54B | 6.66M | 308.10K | 314.00 | 1.09M | 3.12M |
| Total Debt | 10.00M | 24.14K | 3.53M | 6.76M | 1.58M | 1.25M |
| Total Liabilities | 13.84B | 14.06M | 25.78M | 11.99M | 3.37M | 2.00M |
| Stockholders Equity | 66.82B | 70.12M | 79.07M | 542.35K | 763.14K | 3.77M |
Cash Flow | ||||||
| Free Cash Flow | -13.34M | -13.38B | -14.28M | -2.23M | -1.56M | -2.59M |
| Operating Cash Flow | -13.34M | -13.38B | -14.27M | -2.23M | -1.56M | -2.57M |
| Investing Cash Flow | 0.00 | 0.00 | 27.55M | -275.72K | -427.85K | -22.60K |
| Financing Cash Flow | 14.84M | 19.73B | -12.98M | 1.41M | -35.17K | -208.18K |
Scienture Holdings Technical Analysis
Positive
0.55
Price Trends
0.38
Negative
0.39
Negative
0.52
Negative
Market Momentum
-0.01
Positive
52.62
Neutral
53.06
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SCNX, the sentiment is Positive. The current price of 0.55 is above the 20-day moving average (MA) of 0.36, above the 50-day MA of 0.38, and above the 200-day MA of 0.52, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 52.62 is Neutral, neither overbought nor oversold. The STOCH value of 53.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SCNX.
Scienture Holdings Risk Analysis
Scienture Holdings disclosed 45 risk factors in its most recent earnings report. Scienture Holdings reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Scienture Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $15.04M | -0.15 | -44.11% | ― | -73.18% | 92.38% | |
| ― | $2.35M | -0.01 | -8.26% | ― | -28.30% | -86.74% | |
41 Neutral | $3.57M | ― | -112.81% | ― | 77.50% | 99.28% | |
40 Underperform | $5.39M | -0.21 | 336.68% | ― | 18.05% | 86.68% |
* Healthcare Sector Average
SCNX
Scienture Holdings
0.37
-1.28
-77.58%
ZCMD
Zhongchao
2.03
-846.13
-99.76%
HCTI
Healthcare Triangle
1.76
-310.49
-99.44%
VSEE
VSee Health
0.11
-1.27
-91.96%
MGRX
Mangoceuticals, Inc.
0.37
-1.16
-75.99%
Scienture Holdings Corporate Events
Executive/Board Changes
Scienture Holdings Announces CFO Resignation, Names Interim Successor
Neutral
May 29, 2026
On May 26, 2026, Scienture Holdings, Inc. announced that Chief Financial Officer Eric Sherb resigned for personal reasons, with the company emphasizing that his departure did not stem from any dispute with management or the board. The move marks a...
Business Operations and StrategyRegulatory Filings and Compliance
Scienture Holdings Issues Updated Investor Presentation Disclosure
Neutral
May 5, 2026
On May 5, 2026, Scienture Holdings, Inc. posted a revised investor presentation on its website to support upcoming meetings with analysts, potential investors and other interested parties. The presentation is described as summary information that ...
Business Operations and StrategyPrivate Placements and Financing
Scienture Holdings Secures $11.4 Million Structured Financing Deal
Negative
May 1, 2026
On April 27, 2026, Scienture Holdings, Inc. entered into and closed a financing deal with Streeterville Capital, LLC, issuing two secured promissory notes totaling $11.42 million, with $8 million delivered at closing and $3 million placed in a con...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.